Crystallisation of aspirin via simulated pulmonary surfactant monolayers and lung-specific additives.

Michael Davies, Zoe Taylor, Andrew Leach, James Ren, Paul Gibbons

Research output: Contribution to journalArticle

1 Citation (Scopus)
6 Downloads (Pure)

Abstract

Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population. Numerous methods exist to administer analgesic medication (e.g. aspirin) to the body however inherent drawbacks limit patient acceptability. The inhaled route offers promise to facilitate the administration of medication to the body. Here, we consider the crystallisation behaviour of aspirin, our model therapeutic agent, when in contact with material of relevance to the lung. Thus, our approach aims to better understand the interaction between drug substances and the respiratory tract. Langmuir monolayers composed of a mixed surfactant system were supported on an aqueous subphase containing aspirin (7.5 mg/ml). The surfactant film was compressed to either 5mN/m (i.e. inhalation end point) or 50 mN/m (i.e. exhalation end point), whilst located within a humid environment for 16 h. Standard cooling crystallisation procedures were employed to produce control samples. Antisolvent crystallisation in the presence or absence of lung‐specific additives was conducted. All samples were analysed via scanning electron microscopy and X‐ray diffraction. Drug‐surfactant interactions were confirmed via condensed Langmuir isotherms. Scanning electron microscopy analysis revealed plate‐like morphology. The crystallisation route dictated both the crystal habit and particle size distribution. Dominant reflections were the (100) and (200) aspects. The main modes of interaction were hydrogen bonding, hydrophobic associations, and van der Waals forces. Here, we have demonstrated the potential of antisolvent crystallisation with lung‐specific additives to achieve control over drug crystal morphology. The approach taken can be applied in respirable formulation engineering.
Original languageEnglish
Pages (from-to)864-872
JournalSurface and Interface Analysis
Volume49
Issue number9
Early online date4 Apr 2017
DOIs
Publication statusE-pub ahead of print - 4 Apr 2017

Fingerprint

Pulmonary Surfactants
Crystallization
lungs
Aspirin
Monolayers
Surface active agents
surfactants
crystallization
Surface-Active Agents
drugs
routes
Drug interactions
exhalation
Van der Waals forces
Crystals
Scanning electron microscopy
scanning electron microscopy
crystal morphology
pain
monomolecular films

Keywords

  • inhaled drug delivery
  • Langmuir monolayers
  • aspirin
  • antisolvent crystallisation
  • X-ray diffraction (XRD)
  • scanning electron microscopy (SEM)

Cite this

Davies, Michael ; Taylor, Zoe ; Leach, Andrew ; Ren, James ; Gibbons, Paul. / Crystallisation of aspirin via simulated pulmonary surfactant monolayers and lung-specific additives. In: Surface and Interface Analysis. 2017 ; Vol. 49, No. 9. pp. 864-872.
@article{0642264dd86843378380c14dc5e87758,
title = "Crystallisation of aspirin via simulated pulmonary surfactant monolayers and lung-specific additives.",
abstract = "Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population. Numerous methods exist to administer analgesic medication (e.g. aspirin) to the body however inherent drawbacks limit patient acceptability. The inhaled route offers promise to facilitate the administration of medication to the body. Here, we consider the crystallisation behaviour of aspirin, our model therapeutic agent, when in contact with material of relevance to the lung. Thus, our approach aims to better understand the interaction between drug substances and the respiratory tract. Langmuir monolayers composed of a mixed surfactant system were supported on an aqueous subphase containing aspirin (7.5 mg/ml). The surfactant film was compressed to either 5mN/m (i.e. inhalation end point) or 50 mN/m (i.e. exhalation end point), whilst located within a humid environment for 16 h. Standard cooling crystallisation procedures were employed to produce control samples. Antisolvent crystallisation in the presence or absence of lung‐specific additives was conducted. All samples were analysed via scanning electron microscopy and X‐ray diffraction. Drug‐surfactant interactions were confirmed via condensed Langmuir isotherms. Scanning electron microscopy analysis revealed plate‐like morphology. The crystallisation route dictated both the crystal habit and particle size distribution. Dominant reflections were the (100) and (200) aspects. The main modes of interaction were hydrogen bonding, hydrophobic associations, and van der Waals forces. Here, we have demonstrated the potential of antisolvent crystallisation with lung‐specific additives to achieve control over drug crystal morphology. The approach taken can be applied in respirable formulation engineering.",
keywords = "inhaled drug delivery, Langmuir monolayers, aspirin, antisolvent crystallisation, X-ray diffraction (XRD), scanning electron microscopy (SEM)",
author = "Michael Davies and Zoe Taylor and Andrew Leach and James Ren and Paul Gibbons",
year = "2017",
month = "4",
day = "4",
doi = "10.1002/sia.6234",
language = "English",
volume = "49",
pages = "864--872",
journal = "Surface and Interface Analysis",
issn = "0142-2421",
publisher = "John Wiley & Sons",
number = "9",

}

Crystallisation of aspirin via simulated pulmonary surfactant monolayers and lung-specific additives. / Davies, Michael; Taylor, Zoe; Leach, Andrew; Ren, James; Gibbons, Paul.

In: Surface and Interface Analysis, Vol. 49, No. 9, 04.04.2017, p. 864-872.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Crystallisation of aspirin via simulated pulmonary surfactant monolayers and lung-specific additives.

AU - Davies, Michael

AU - Taylor, Zoe

AU - Leach, Andrew

AU - Ren, James

AU - Gibbons, Paul

PY - 2017/4/4

Y1 - 2017/4/4

N2 - Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population. Numerous methods exist to administer analgesic medication (e.g. aspirin) to the body however inherent drawbacks limit patient acceptability. The inhaled route offers promise to facilitate the administration of medication to the body. Here, we consider the crystallisation behaviour of aspirin, our model therapeutic agent, when in contact with material of relevance to the lung. Thus, our approach aims to better understand the interaction between drug substances and the respiratory tract. Langmuir monolayers composed of a mixed surfactant system were supported on an aqueous subphase containing aspirin (7.5 mg/ml). The surfactant film was compressed to either 5mN/m (i.e. inhalation end point) or 50 mN/m (i.e. exhalation end point), whilst located within a humid environment for 16 h. Standard cooling crystallisation procedures were employed to produce control samples. Antisolvent crystallisation in the presence or absence of lung‐specific additives was conducted. All samples were analysed via scanning electron microscopy and X‐ray diffraction. Drug‐surfactant interactions were confirmed via condensed Langmuir isotherms. Scanning electron microscopy analysis revealed plate‐like morphology. The crystallisation route dictated both the crystal habit and particle size distribution. Dominant reflections were the (100) and (200) aspects. The main modes of interaction were hydrogen bonding, hydrophobic associations, and van der Waals forces. Here, we have demonstrated the potential of antisolvent crystallisation with lung‐specific additives to achieve control over drug crystal morphology. The approach taken can be applied in respirable formulation engineering.

AB - Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population. Numerous methods exist to administer analgesic medication (e.g. aspirin) to the body however inherent drawbacks limit patient acceptability. The inhaled route offers promise to facilitate the administration of medication to the body. Here, we consider the crystallisation behaviour of aspirin, our model therapeutic agent, when in contact with material of relevance to the lung. Thus, our approach aims to better understand the interaction between drug substances and the respiratory tract. Langmuir monolayers composed of a mixed surfactant system were supported on an aqueous subphase containing aspirin (7.5 mg/ml). The surfactant film was compressed to either 5mN/m (i.e. inhalation end point) or 50 mN/m (i.e. exhalation end point), whilst located within a humid environment for 16 h. Standard cooling crystallisation procedures were employed to produce control samples. Antisolvent crystallisation in the presence or absence of lung‐specific additives was conducted. All samples were analysed via scanning electron microscopy and X‐ray diffraction. Drug‐surfactant interactions were confirmed via condensed Langmuir isotherms. Scanning electron microscopy analysis revealed plate‐like morphology. The crystallisation route dictated both the crystal habit and particle size distribution. Dominant reflections were the (100) and (200) aspects. The main modes of interaction were hydrogen bonding, hydrophobic associations, and van der Waals forces. Here, we have demonstrated the potential of antisolvent crystallisation with lung‐specific additives to achieve control over drug crystal morphology. The approach taken can be applied in respirable formulation engineering.

KW - inhaled drug delivery

KW - Langmuir monolayers

KW - aspirin

KW - antisolvent crystallisation

KW - X-ray diffraction (XRD)

KW - scanning electron microscopy (SEM)

U2 - 10.1002/sia.6234

DO - 10.1002/sia.6234

M3 - Article

VL - 49

SP - 864

EP - 872

JO - Surface and Interface Analysis

JF - Surface and Interface Analysis

SN - 0142-2421

IS - 9

ER -